Alpha Cognition’s 1Q26 strengthened the ZUNVEYL launch thesis in long term care, with net product revenue increasing 40% q/q to $3.5M, March marking the strongest demand month since launch, and April tracking above March. More importantly, adoption quality continued to improve across prescribers and facilities, suggesting ZUNVEYL is moving further beyond initial trial use and becoming more integrated into LTC prescribing patterns. In our view, the next phase of the 2026 launch will be driven by field productivity, downstream PBM implementation, and real-world evidence that can support prescriber confidence and payer access.